Search
H3B-8800
go.drugbank.com/drugs/DB14017InvestigationalH3B-8800 is a novel spliceosome inhibitor developed by H3 Biomedicine [L2551]. … H3B-8800 was granted orphan drug status by the FDA in August 2017 and is in clinical trials for the treatment of acute myelogenous leukemia and chronic myelomonocytic leukemia [L2551].
Synonyms: (2S,3S,4E,6S,7R,10R)-7,10-Dihydroxy-3,7-dimethyl-12-oxo-2-[(2E,4E,6R)-6-(2-pyridinyl)-2,4-heptadien-2-yl]oxacyclododec-4-en-6-yl 4-methyl-1-piperazinecarboxylate, (2S,3S,4E,6S,7R,10R)-7,10-Dihydroxy-3,7-Dimethyl-12-Oxo-2-[(2E,4E,6R)-6-(Pyridin-2-Yl)Hepta-2,4-Dien-2-Yl]Oxacyclododec-4-En-6-Yl 4-Methylpiperazine-1-CarboxylateAmobarbital
go.drugbank.com/drugs/DB01351ApprovedIllicitAdverse effects are mainly a consequence of dose-related CNS depression and the risk of dependence with continued use is high. (From Martindale, The Extra Pharmacopoeia, 30th ed, p565) … A barbiturate with hypnotic and sedative properties (but not antianxiety).
Bimoclomol
go.drugbank.com/drugs/DB06258ExperimentalBimoclomol is an investigational drug that induces stress proteins and has cytoprotective effects.
Golotimod
go.drugbank.com/drugs/DB05475InvestigationalSCV-07 (g -D-glutamyl-L-tryptophan) is a novel synthetic dipeptide that acts broadly on the Toll-like receptor pathway. … SCV-07 has shown efficacy in treating various viral and bacterial infections.
Proxalutamide
go.drugbank.com/drugs/DB16065InvestigationalProxalutamide is under investigation in clinical trial NCT03899467 (The Safety and Tolerability of Proxalutamide (GT0918) in Subjects With Metastatic Castrate Resistant Prostate Cancer).
Tiapride
go.drugbank.com/drugs/DB13025InvestigationalTiapride is a selective D2 and D3 dopamine receptor blocker in the brain.
Products: TIAPRID 1A PHARMA 200MG, TIAPRID 100 1A PHARMAAlferminogene tadenovec
go.drugbank.com/drugs/DB05306InvestigationalAlferminogene tadenovec, Cardium’s lead product candidate, is being developed for the potential treatment of myocardial ischemia that gives rise to angina symptoms associated with coronary heart disease … Alferminogene tadenovec represents a new therapeutic class of biologics designed to promote angiogenesis and thereby improve blood flow following a one-time intracoronary administration from a standard